09:22 AM EDT, 05/08/2024 (MT Newswires) -- Syndax Pharmaceuticals ( SNDX ) reported a Q1 net loss Wednesday of $0.85 per diluted share, wider than a loss of $0.59 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.97.

The company didn't report any revenue, as expected.

As of Mar. 31, the company had $522.0 million in cash, cash equivalents, short and long-term investments and expected it could fund its research, clinical development and commercial operations through 2026.